Abstract
Marfan syndrome (MFS) is a genetic disorder affecting 1 in 5,000 individuals. The diagnosis is made using a combination of genetic testing and the revised Ghent criteria. MFS is associated with the cardiovascular-related risks of aortic dilation and dissection. Therefore, the main goal of medical therapy is blood pressure control using beta-blockers and lifestyle modification. Prophylactic surgical intervention remains the single, definitive measure in preventing dissection or rupture. Nurse practitioners must be vigilant in caring for this population as these cardiovascular risks can be reduced by early identification and diagnosis and timely intervention.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
